Key Dates

Related Announcements

• August 14, 2024 - Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required). See RFA-CA-24-025 

Issued by

National Cancer Institute (NCI)

Purpose

This Notice of Correction is to inform applicants of a change in the Application and Submission Information in RFA-CA-24-025, Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required).

Changes to the NOFO are shown below:

Part 2. Full Text of Announcement, Section IV.2 Application and Submission Information, Content and Form of Application Submission, R&R Budget

Currently reads:

Clinical Trials Auditing Unit

• For intermediate and low-risk trials (e.g., FDA approved agent, over the counter medication or supplement, agent with low toxicity profile), follow-up audits will be conducted every 3 years on >50% of AOs meeting the accrual threshold (?3 participants)

Corrected/revised to read (in bold italics):

Clinical Trials Auditing Unit

• For intermediate and low-risk trials (e.g., FDA approved agent, over the counter medication or supplement, agent with low toxicity profile), follow-up audits will be conducted every 3 years on >50% of AOs meeting the accrual threshold (greater than or equal to 3 participants).

Part 2. Full Text of Announcement, Section IV.2 Application and Submission Information, Content and Form of Application Submission, R&R Budget

Currently reads:

Restricted Funds for Support of Young/Emerging Investigators

An amount of $125,000 per year (direct costs) should be entered as "Restricted Funds" under the "Other Expenses" category in the Budget form for years 1-5.

Corrected/revised to read (in bold italics):

An amount of $125,000 per year (direct costs) should be entered as "Restricted Funds" under the "Other Expenses" category in the Budget form for years 1-6.

All other aspects of RFA-CA-24-025 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Eva Szabo, MD
National Cancer Institute (NCI)
Telephone: 240-276-7011
Fax: 240-276-7848
Email: szaboe@mail.nih.gov

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov

Financial/Grants Management Contact(s)

Sean Hine
National Cancer Institute (NCI)
Telephone: 301-276-6291
Email: hines@mail.nih.gov